Abstract
Based on the complex pathophysiology of type 2 diabetes and atherosclerosis we hypothesized a dynamic change in prognostic value of cardiovascular biomarkers over time. In this prospective study 746 patients with type 2 diabetes mellitus, being followed up for 60months were analysed. The primary endpoint was defined as unplanned hospitalization for cardiovascular disease or death. Beside others, especially the prognostic performance of the biomarkers of interest (GDF-15, NT-proBNP, hs-TnT) was evaluated in relation to quartiles of diabetes duration. In patients having a diabetes duration below 7years lnGDF-15 (HR 2.84; p<0.01) and lnhs-TnT (HR 2.96; p<0.01) were significant predictors of the primary endpoint. LnAge (HR 40.01; p<0.01) and lnNT-proBNP (HR 1.56; p=0.03) were significant predictors in patients with a diabetes duration between 7 and 12years. In the third quartile (diabetes duration 12-22years) lnurinary albumin to creatinine ratio (HR 1.25; p=0.005) and lnNT-proBNP (HR 2.13, p<0.001) predicted the endpoint. In patients with a diabetes duration above 22years, lnAge (HR 75.35; p=0.001) and lnNT-proBNP (HR 2.0; p<0.01) were the only significant predictors of the endpoint. Prognostic power of cardiovascular biomarkers changes dynamically in relation to duration of type 2 diabetes mellitus. In patients with shorter duration of the disease markers of subclinical cardiovascular dysfunction and inflammation perform better than markers of systemic advanced organ dysfunction and cardiovascular disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.